Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

200 ppm Nitric Oxide

Preclinical

TTomsk National Research Medical Center of the Russian Academy of Sciences

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Nosocomial PneumoniaActive, not recruiting

Nosocomial PneumoniaPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

PreclinicalActive, not recruiting

Nosocomial Pneumonia

NCT06170372

Clinical

Trials by Indication[1]

Nosocomial Pneumonia1 trial

The Effectiveness of Adding Multiple Intermittent High-dose Inhalations of Nitric Oxide to Standard Antibacterial Therapy in the Treatment of Pneumonia

Active, not recruiting·TTomsk National Research Medical Center of the Russian Academy of Sciences·Preclinical·NCT06170372·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 200 ppm Nitric Oxide. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 200 ppm Nitric Oxide. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tomsk National Research Medical Center of the Russian Academy of Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: TTomsk National Research Medical Center of the Russian Academy of Sciences

Related News